Simple Summary Pain associated with cancer diagnoses is a serious concern and one of
the most common symptoms reported by cancer patients. The insufficient relief of cancer …

Hematologic malignancies are a heterogeneous group of diseases with unique illness
trajectories, treatment paradigms, and potential for curability, which affect patients' palliative …

Anaemia and iron deficiency (ID) are frequent complications in patients with solid tumours or
haematological malignancies, particularly in patients treated with chemotherapeutic agents …

The heterogeneity of myelodysplastic syndromes (MDSs) has made evaluating patient
response to treatment challenging. In 2006, the International Working Group (IWG) proposed …

In myelodysplastic syndromes (MDS), health-related quality of life (HRQoL) represents a
relevant patient-reported outcome, which is essential in individualized therapy planning …

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disorder caused by complement-
mediated hemolysis and thrombosis through the alternative pathway. The most common …

Background The clinical presentation of myelodysplastic syndromes is highly variable and
so accurate prediction of outcomes in these patients is crucial. We aimed to assess whether …

Luspatercept is an approved therapy for selected patients with lower risk myelodysplasia
requiring transfusion despite erythropoiesis-stimulating agents, based on the early results of …

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic, acquired, hematologic, life-
threatening disease characterized by thrombosis, impaired bone marrow function, and …

Disease-specific measures of quality of life can improve assessment of disease-related
symptoms and psychosocial sequelae. We report on the development and validation of the …